Pharmacokinetics and Pharmacodynamics of Avian Egg-Yolk Derived Pure Anti-Snake Venom in Healthy and Disease Animal-Model

Korah, Mejo C; Hima, SP; Raj, Silpa; Anil, Arya; Harikrishnan, V. S.; Krishnan, Lissy K.

doi:10.1016/j.xphs.2022.02.008

Cited by 3 publications

(1 citation statement)

References 42 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The IgY antibodies specifically recognized the venom and as previously mentioned, did not activate the complement system, suggesting the possibility of safe re-administration until the resolution of intoxication symptoms in animals not developing ADE [ 60 , 61 ]. Since oral administration of IgY in humans has been shown to be effective and without side-effects, its parenteral administration needs further investigation to determine its safety, tolerability, and efficacy [ 62 , 63 , 64 ].…”

Section: Pharmacokinetics and Pharmacodynamics Of Igymentioning

confidence: 99%

IgY Antibodies as Biotherapeutics in Biomedicine

León-Núñez¹,

Vizcaíno-López²,

Escorcia³

et al. 2022

Antibodies

View full text Add to dashboard Cite

Since the discovery of antibodies by Emil Von Behring and Shibasaburo Kitasato during the 19th century, their potential for use as biotechnological reagents has been exploited in different fields, such as basic and applied research, diagnosis, and the treatment of multiple diseases. Antibodies are relatively easy to obtain from any species with an adaptive immune system, but birds are animals characterized by relatively easy care and maintenance. In addition, the antibodies they produce can be purified from the egg yolk, allowing a system for obtaining them without performing invasive practices, which favors the three “rs” of animal care in experimentation, i.e., replacing, reducing, and refining. In this work, we carry out a brief descriptive review of the most outstanding characteristics of so-called “IgY technology” and the use of IgY antibodies from birds for basic experimentation, diagnosis, and treatment of human beings and animals.

show abstract

Section: Pharmacokinetics and Pharmacodynamics Of Igymentioning

confidence: 99%

IgY Antibodies as Biotherapeutics in Biomedicine

León-Núñez¹,

Vizcaíno-López²,

Escorcia³

et al. 2022

Antibodies

View full text Add to dashboard Cite

show abstract

Pharmacological safety of dimethoxy curcumin-human serum albumin conjugate for potential therapeutic purpose

Korah

Harikrishnan

Krishnan

et al. 2023

Can. J. Physiol. Pharmacol.

View full text Add to dashboard Cite

Medicinal properties of curcumin are widely published. Previously researchers used curcuminoid mixture comprising three chemical forms out of which, the highest quantity is the most active molecule - dimethoxy curcumin (DMC). Reduced bioavailability, poor aqueous solubility and quick hydrolytic degradation of DMC have projected challenges limiting its therapeutic value. However, selective conjugation of DMC with human serum albumin (HSA) enhances drug stability and solubility by several folds. Studies using animal models demonstrated potential anti-cancer/anti-inflammatory effects of DMCHSA; both studies showed results of local administration in peritoneal cavity and rabbit knee joint. DMC has prospects as an intravenous therapeutic agent because carrier is HSA. However, before in vivo testing, important preclinical data required are toxicological safety and bioavailability of soluble forms of DMC. This study evaluated absorption, distribution, metabolism and excretion (ADME) of DMCHSA. Imaging technology and molecular analysis proved bio-distribution. Study also assessed pharmacological safety of DMCHSA in mice in terms of its acute and sub-acute toxicity complying with regulatory toxicology. Overall, the study demonstrated safety pharmacology of DMCHSA upon intravenous infusion. This is a novel study establishing safety of highly soluble and stable formulation of DMCHSA qualifying it for intravenous administration and further efficacy evaluation in suitable disease models.

show abstract

Pre-clinical Efficacy and Immunogenicity of IgY Antibodies Directed against Crotalus durissus cumanensis Venom

Montero,

Zerpa,

Neves

et al. 2024

JCTV

View full text Add to dashboard Cite

Background:: Crotalus durissus cumanensis (C.d.c.) is the most widely distributed snake in Venezuela, causing the majority of snakebite envenoming Objective:: The purpose of this study was to produce IgY antibodies against a C.d.c. venom pool from different Venezuelan regions and evaluate their neutralization capacity on various venom toxic activ-ities. Methods:: Anti-C.d.c. venom antibodies are purified from chicken egg yolks by precipitation with polyethylene glycol and further analyzed by Multiple Antigen Blot Assay, indirect ELISA, Western blot, and Inhibition assays. In addition, we evaluate the phospholipase, edematogenic, and hemor-rhagic activities. In addition, a new envenoming simulation study using anti-C.d.c. venom IgY in mice is presented. Results:: In this study, we show that anti-C.d.c. venom IgY is capable of neutralizing 4LD50 doses of the Cdc venom (i.e., 1.76 mg of IgY neutralized 14 μg of C.d.c. venom) and effectively neutralizing the phospholipase, edematogenic and hemorrhagic activities. Additionally, the anti C.d.c. venom IgY specifically recognizes polypeptide bands with apparent molecular masses of ~ 54.55, 30.39, 24.1, 14.02, and 9.44 kDa by western blot. The IgY specificity is demonstrated by a dose-dependent inhi-bition, in which antibodies pre-adsorbed with the C.d.c. venom does not recognize the proteins con-tained in the venom. Furthermore, in the simulation study of envenoming, the mice inoculated with IgY showed no response. Conclusion:: Our results support the use of anti-venom IgY as an alternative to traditional equine therapy in animals and, eventually, in human patients bitten by C.d.c snakes. conclusion: Our results support the use of anti-venom IgY as an alternative to traditional equine therapy in animals and, eventually, in human patients bitten by C.d.c snakes.

show abstract

Pharmacokinetics and Pharmacodynamics of Avian Egg-Yolk Derived Pure Anti-Snake Venom in Healthy and Disease Animal-Model

Cited by 3 publications

References 42 publications

IgY Antibodies as Biotherapeutics in Biomedicine

IgY Antibodies as Biotherapeutics in Biomedicine

Pharmacological safety of dimethoxy curcumin-human serum albumin conjugate for potential therapeutic purpose

Pre-clinical Efficacy and Immunogenicity of IgY Antibodies Directed against Crotalus durissus cumanensis Venom

Contact Info

Product

Resources

About